By-product of the manufacture of coffee roasted for the prevention and treatment of metabolic syndrome

The CSIC and the University of Granada (UGR) have developed a preventive and therapeutic application against the metabolic syndrome from coffee silverskin, a residue form roasted coffee. Bioactivity on glucose and lipid metabolism is due to the composition in chlorogenic acid and caffeine from the silverskin.

We seek nutraceutical and pharmaceutical companies interested in developing and commercializing these compounds, under a patent license.

**Offer of License of Patent**

**Trials in Animal Model (Wistar rat)**

Metabolic syndrome is a combination in a single individual of various risk factors, including dyslipidemia, hyperglycemia, insulin resistance and obesity. These factors share pathophysiological mechanisms and often are combined on to degenerate in diabetes mellitus type 2 and cardiovascular complications associated with changes in the pattern of serum lipids.

The present invention is based on the observation that the administration (35 days, 140 mg/kg/day) of an extract from coffee silverskin in a rat model of Wistar, in which is induced diabetes mellitus type 2, produces a decreased resistance to insulin, hypoglycemic effect, and antidiabetogenic effect.

In addition, the extract of coffee silverskin administered jointly with a load of glucose presents hypoglycemic effect and an improved tolerance to glucose intake in a model of healthy Wistar rats.

**Main Advantages and its application**

- The main advantage is the use of a bioactive product retrieved from a waste material that is the coffee silver skin.
- This use allows to prevent the pathologies that make up the metabolic syndrome and its risk factors.

**Patent Status**

Priority established by a Spanish patent application

**For further information please contact**

Antonio Jiménez (Ph.D.)
Technology Transfer Manager
Spanish National Research Council
Tel.: (+34) 91 568 19 30
a.jimenez.escrig@csic.es